Press-release for stocks related to events for gilead sciences, inc.

Prices are updated after-hours

tags : Events entities : Gilead sciences, inc.

save search

New Analyses Presented at ASH 2023 Support the Potential Long-Term Response and Safety of Kite’s Tecartus® in Patients With Aggressive Blood Cancers
Published: 2023-12-12 (Crawled : 07:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology

| -16.47% | O: 0.86% H: 0.49% C: 0.05%
tecartus blood response potential

Gilead Sciences to Present at Upcoming November 2023 Investor Conferences
Published: 2023-11-09 (Crawled : 09:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology

| -14.12% | O: -0.47% H: 0.23% C: -3.29%
sciences

Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023
Published: 2023-11-03 (Crawled : 17:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology

| -17.64% | O: 0.95% H: 0.72% C: -0.5%
meeting hepatitis liver world

Gilead Sciences and Meharry Medical College Highlight Five-Year Impact of Gilead COMPASS Initiative® on HIV in the Southern United States
Published: 2023-08-18 (Crawled : 22:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology

| -12.55% | O: 0.07% H: 0.21% C: -0.88%
initiative sciences hiv impact medical

GILEAD LAUNCHES GLOBAL ALL4LIVER GRANT PROGRAM TO HELP ACHIEVE THE WORLD HEALTH ORGANIZATION’S GOAL OF VIRAL HEPATITIS ELIMINATION BY 2030
Published: 2023-07-28 (Crawled : 22:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology

| -12.56% | O: -0.12% H: 1.18% C: 0.58%
hepatitis health world global grant program

Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023
Published: 2023-05-17 (Crawled : 14:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology

| -14.58% | O: -0.22% H: 1.12% C: 0.85%
asco cancer pipeline care

Gilead Demonstrates Transformative Potential Impact Of Antiviral Innovation at CROI 2023
Published: 2023-02-14 (Crawled : 14:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology

| -23.53% | O: 0.11% H: 0.02% C: -2.18%
antiviral impact potential innovation

Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy (ZUMA-5 Trial) - 52% of Patients With Indolent Lymphomas Continued to Have Ongoing Responses at a Median Follow-Up of 40.5 Months
Published: 2022-12-12 (Crawled : 19:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology

| -23.95% | O: -0.14% H: 0.81% C: 0.79%
yescarta ongoing lymphomas t-cell therapy

Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease
Published: 2022-11-01 (Crawled : 16:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology

| -14.73% | O: -0.25% H: 1.65% C: 1.38%
meeting treatment hepatitis fibrosis liver disease living

Jounce Therapeutics to Participate in Cowen & Co. 42nd Annual Health Care Conference
Published: 2022-02-28 (Crawled : 14:30) - biospace.com/
JNCE | $1.88 -2.59% -1.85% 0

Health Technology

| -73.8% | O: -0.96% H: 4.46% C: 3.32%
GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology

| 9.92% | O: -1.0% H: 0.37% C: 0.25%
health conference therapeutics

Second Genome to Host Virtual KOL Event to Discuss the Role of Mucosal Healing and PAI-1/2 in Inflammatory Bowel Disease on February 23
Published: 2022-02-14 (Crawled : 12:30) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology

| 7.86% | O: 0.1% H: 0.1% C: -1.58%
disease

Gilead to Present Latest Antiviral Research and Development Data at CROI 2022 Addressing Urgent Global Needs
Published: 2022-02-08 (Crawled : 17:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology

| 4.53% | O: -0.27% H: 0.81% C: -0.2%
research test antiviral

Gilead Presents Long-Term Switch Data Reinforcing Biktarvy® as a Treatment Option for a Broad Range of People Living With HIV
Published: 2021-10-21 (Crawled : 13:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology

| 0.06% | O: 0.34% H: 0.15% C: -0.15%
treatment hiv

Gilead to Present Latest Antiviral Research Data Addressing Urgent Global Needs in Infectious Disease at IDWeek 2021
Published: 2021-09-20 (Crawled : 13:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology

| -5.55% | O: 0.14% H: 1.4% C: 0.04%
disease infectious disease test antiviral research

Second Genome Presents Preclinical Data at ESMO 2021 Demonstrating that a Novel Microbiome-Derived Peptide, SG-3-00802, Reverses Resistance to Anti-Programmed Death Protein-1 (PD-1) Therapy
Published: 2021-09-16 (Crawled : 11:33) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology

| -6.77% | O: 0.06% H: 0.08% C: -0.65%
therapy preclinical pre-clinical

Gilead to Present More Than 70 Abstracts From Diverse Liver Disease Programs At The International Liver Congress™ 2021
Published: 2021-06-21 (Crawled : 11:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology

| 0.44% | O: 0.57% H: 0.86% C: 0.54%
disease liver disease liver

Second Genome to Present Big Data Analytics Capabilities at the Microbiome Data Congress
Published: 2021-06-09 (Crawled : 12:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology

| -0.9% | O: 0.09% H: 2.4% C: 1.6%
analytics data analytics

Second Genome to Present at the Jefferies Microbiome-Based Therapeutics Summit
Published: 2021-04-15 (Crawled : 13:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology

| 2.45% | O: -0.92% H: 2.6% C: 1.65%

Gilead Sciences to Present at Upcoming Investor Conferences
Published: 2021-02-18 (Crawled : 19:00) - biospace.com/
GILD | News | $66.16 -1.15% -1.16% 6.4M

Health Technology